Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 4:36 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 1,709 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all
Completed Phase 3 Interventional

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

NCT00076232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Herpes Genitalis
Interventions
Acyclovir, Acyclovir placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2010 · Synced Nov 2, 2026, 4:36 PM EST
Completed No phase listed Observational

Pericardial Fat and Inflammation in HIV Patients and Controls

NCT02399384
View directory record Official record
Conditions
Coronary Artery Disease, Human Immunodeficiency Virus (HIV)
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 2, 2026, 4:36 PM EST
Active, not recruiting Phase 2 Interventional

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

NCT06497504
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Bakersfield, California • San Francisco, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 2, 2026, 4:36 PM EST
Terminated No phase listed Observational

Observational Study of HIV-Infected Subjects With X4-Tropic or Non-Phenotypeable Virus

NCT00321438
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
15
States / cities
Los Angeles, California • Tarzana, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 2 Interventional Results available

Randomized Placebo-Controlled Trial of Atorvastatin in HIV-Positive Patients Not on Antiretroviral Therapy

NCT00367458
View directory record Official record
Conditions
HIV
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
San Diego, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Nov 2, 2026, 4:36 PM EST
Completed No phase listed Observational

Specimen Repository for HIV Immunopathogenesis

NCT03579381
View directory record Official record
Conditions
HIV-1-infection, Acute HIV Infection
Interventions
Not listed
Lead sponsor
AIDS Healthcare Foundation
Other
Eligibility
18 Years and older
Enrollment
9 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Nov 2, 2026, 4:36 PM EST
Terminated Phase 1 Interventional

Safety and Tolerability of Z-100 in Patients With Early HIV Infection

NCT00016692
View directory record Official record
Conditions
HIV Infections
Interventions
Z-100
Drug
Lead sponsor
Zeria Pharmaceutical
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2006 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 1 Interventional

The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection

NCT00001036
View directory record Official record
Conditions
HIV Infections
Interventions
Thymalfasin, Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 3 Interventional Results available

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

NCT01499199
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 1 Interventional Results available

Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

NCT02778204
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 3 Days
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 2 Interventional

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

NCT00002233
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 4:36 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Messaging Intervention to Present New HIV Prevention Options for Men Who Have Sex With Men (MSM)

NCT03666247
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
HealthMindr Application, Waitlist
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
1,229 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

NCT00472719
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 1 Interventional

Raltegravir as Early Therapy in African-Americans Living With HIV Study

NCT00667433
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir + Truvada
Drug
Lead sponsor
David A Wohl, MD
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Nov 2, 2026, 4:36 PM EST
Not listed Not applicable Interventional

Adherence Connection for Counseling, Education, and Support

NCT02753049
View directory record Official record
Conditions
HIV-infection/AIDS
Interventions
Peer led mHelath behavioral intervention
Behavioral
Lead sponsor
New York University
Other
Eligibility
16 Years to 29 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Nov 2, 2026, 4:36 PM EST
Completed Not applicable Interventional

Cooperative Re-Engagement Controlled Trial (CoRECT)

NCT02693145
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Anti-Retroviral Treatment and Access to Services (ARTAS)
Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
1,893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Nov 2, 2026, 4:36 PM EST
Terminated Phase 4 Interventional

Liraglutide for HIV-associated Neurocognitive Disorder

NCT02743598
View directory record Official record
Conditions
HIV Infection, Diabetes Mellitus Type 2, Obesity, Overweight, Metabolic Syndrome
Interventions
Liraglutide
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

NCT00085917
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Nov 2, 2026, 4:36 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

NCT06724640
View directory record Official record
Conditions
HIV Infections
Interventions
VH4011499 low dose Injection, VH4011499 high dose Injection, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 2, 2026, 4:36 PM EST
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

NCT05470491
View directory record Official record
Conditions
HIV, Hematologic Malignancies
Interventions
RIC, GVHD prophylaxis, allo HCT, Plerixafor, Maraviroc
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 4 Interventional

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388
View directory record Official record
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Nov 2, 2026, 4:36 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Preparedness Study - HPV Vaccine

NCT01489527
View directory record Official record
Conditions
Sexual Transmission of Infection
Interventions
Gardasil Vaccine, Placebo
Biological · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years to 24 Years · Female only
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Nov 2, 2026, 4:36 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

NCT04003103
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Islatravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
4
States / cities
Hollywood, Florida • Baltimore, Maryland • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Nov 2, 2026, 4:36 PM EST
Active, not recruiting Phase 1 Interventional

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

NCT04340596
View directory record Official record
Conditions
HIV Infection
Interventions
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 2, 2026, 4:36 PM EST